Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duloxetine for depression and sleep problems in patients with multiple sclerosis
IRCT20250116064399N1Phase 2Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) and sleep disorder comparing Duloxetine with Placebo (2 arms). Primary endpoints: Depressive symptoms in MS patients and Sleep quality in MS patients. Started Feb 2025; status: completed.
02
Drugs
duloxetine
03
Conditions
major depressive disorder (MDD)sleep disorder
Beyond the preview
Go deeper on IRCT20250116064399N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250116064399N1.